+Search query
-Structure paper
Title | LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection. |
---|---|
Journal, issue, pages | bioRxiv, Year 2020 |
Publish date | Oct 9, 2020 |
Authors | Bryan E Jones / Patricia L Brown-Augsburger / Kizzmekia S Corbett / Kathryn Westendorf / Julian Davies / Thomas P Cujec / Christopher M Wiethoff / Jamie L Blackbourne / Beverly A Heinz / Denisa Foster / Richard E Higgs / Deepa Balasubramaniam / Lingshu Wang / Roza Bidshahri / Lucas Kraft / Yuri Hwang / Stefanie Žentelis / Kevin R Jepson / Rodrigo Goya / Maia A Smith / David W Collins / Samuel J Hinshaw / Sean A Tycho / Davide Pellacani / Ping Xiang / Krithika Muthuraman / Solmaz Sobhanifar / Marissa H Piper / Franz J Triana / Jorg Hendle / Anna Pustilnik / Andrew C Adams / Shawn J Berens / Ralph S Baric / David R Martinez / Robert W Cross / Thomas W Geisbert / Viktoriya Borisevich / Olubukola Abiona / Hayley M Belli / Maren de Vries / Adil Mohamed / Meike Dittmann / Marie Samanovic / Mark J Mulligan / Jory A Goldsmith / Ching-Lin Hsieh / Nicole V Johnson / Daniel Wrapp / Jason S McLellan / Bryan C Barnhart / Barney S Graham / John R Mascola / Carl L Hansen / Ester Falconer |
PubMed Abstract | SARS-CoV-2 poses a public health threat for which therapeutic agents are urgently needed. Herein, we report that high-throughput microfluidic screening of antigen-specific B-cells led to the ...SARS-CoV-2 poses a public health threat for which therapeutic agents are urgently needed. Herein, we report that high-throughput microfluidic screening of antigen-specific B-cells led to the identification of LY-CoV555, a potent anti-spike neutralizing antibody from a convalescent COVID-19 patient. Biochemical, structural, and functional characterization revealed high-affinity binding to the receptor-binding domain, ACE2 binding inhibition, and potent neutralizing activity. In a rhesus macaque challenge model, prophylaxis doses as low as 2.5 mg/kg reduced viral replication in the upper and lower respiratory tract. These data demonstrate that high-throughput screening can lead to the identification of a potent antiviral antibody that protects against SARS-CoV-2 infection. ONE SENTENCE SUMMARY: LY-CoV555, an anti-spike antibody derived from a convalescent COVID-19 patient, potently neutralizes SARS-CoV-2 and protects the upper and lower airways of non-human primates against SARS-CoV-2 infection. |
External links | bioRxiv / PubMed:33024963 / PubMed Central |
Methods | EM (single particle) |
Resolution | 3.27 Å |
Structure data | EMDB-23156, PDB-7l3n: |
Chemicals | ChemComp-NAG: |
Source |
|
Keywords | VIRAL PROTEIN/IMMUNE SYSTEM / Glycoprotein / VIRAL PROTEIN-IMMUNE SYSTEM complex |